Drugs / Pembrolizumab/Quavonlimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05899049 | Jul 2022 → Jun 2027 expected | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05899049 ↗ |
| Route | Intravenous | “administered Q6W via IV infusion” NCT05899049 ↗ |